太极拳干预治疗膝关节骨性关节炎的随机对照研究

注册号:

Registration number:

ChiCTR2300069339 

最近更新日期:

Date of Last Refreshed on:

2023-05-23 19:39:12 

注册时间:

Date of Registration:

2023-03-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

太极拳干预治疗膝关节骨性关节炎的随机对照研究

Public title:

Tai Chi for Treating Patients with Knee Osteoarthritis: a Randomized Controlled Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

太极拳干预治疗膝关节骨性关节炎的随机对照研究

Scientific title:

Tai Chi for Treating Patients with Knee Osteoarthritis: a Randomized Controlled Trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

岳虹妤 

研究负责人:

姚斐 

Applicant:

Yue Hongyu 

Study leader:

Yao Fei 

申请注册联系人电话:

Applicant telephone:

+86 157 0006 6813

研究负责人电话:

Study leader's
telephone:

+86 135 8597 5106

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yhy03040506@163.com

研究负责人电子邮件:

Study leader's E-mail:

doctoryaofei@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市静安区芷江中路274号

研究负责人通讯地址:

上海市静安区芷江中路274号

Applicant address:

274 Zhijiang Middle Road, Jing'an District, Shanghai, China

Study leader's address:

274 Zhijiang Middle Road, Jing'an District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市中医医院

Applicant's institution:

Shanghai Municipal Hospital of Traditional Chinese Medicine

研究负责人所在单位:

上海市中医医院

Affiliation of the Leader:

Shanghai Municipal Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022SHL-KY-98-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市中医医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Municipal Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022-11-21 00:00:00

伦理委员会联系人:

凌丽

Contact Name of the ethic committee:

Ling Li

伦理委员会联系地址:

上海市静安区芷江中路274号

Contact Address of the ethic committee:

274 Zhijiang Middle Road, Jing'an District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市中医医院

Primary sponsor:

Shanghai Municipal Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市静安区芷江中路274号

Primary sponsor's address:

274 Zhijiang Middle Road, Jing'an District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市中医医院

具体地址:

上海市静安区芷江中路274号

Institution
hospital:

Shanghai Municipal Hospital of Traditional Chinese Medicine

Address:

274 Zhijiang Middle Road, Jing'an District, Shanghai, China

经费或物资来源:

上海市中医院未来计划科技发展项目

Source(s) of funding:

Future Plan for Traditional Chinese Medicine Development of Science and Technology of Shanghai Municipal Hospital of Traditional Chinese Medicine

研究疾病:

膝关节骨性关节炎  

Target disease:

Knee Osteoarthritis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

验证太极对膝骨关节炎患者膝部疼痛和功能障碍的有效性,并探索其在增强股四头肌力量和降低膝关节疼痛水平之间的相关性。  

Objectives of Study:

To verify that TC provides positive effect on pain and physical functions of KOA in middle-aged and older adults compared with health education as the passive control, and to prove that Tai Chi increases muscle strength of the quadriceps sufficiently to lower pain levels of knees.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.膝部有外伤及手术史者或膝部合并患有肿瘤、结核、骨髓炎等疾病; 2.近6个月关节镜检查或近3个月关节腔内注射激素或透明质酸; 3.医生确定的妨碍运动的重大医疗或身体状况,包括心、肝、肾、脑血管和造血系统的严重急慢性器质性疾病、近期中风、精神疾病、活动性癌症; 4.试验开始前3个月中,每周参与力量训练超过30分钟; 5.近1个月内参加其他临床医学试验研究。

Exclusion criteria:

1. History of knee surgery or combined with tumor, tuberculosis, osteomyelitis in knee joints; 2. Arthroscopy in the past 6 months or intra-articular injection of steroid or hyaluronic acid in the past 3 months; 3. Major medical or physical conditions determined by doctors to preclude exercise, including serious acute or chronic organic diseases of cardiovascular, hepatic, renal, cerebrovascular and hematopoietic systems, recent stroke, psychiatric disease, active cancer; 4. Have participated in strength training more than 30 minutes per week in the past 3 months; 5. Have participated in other clinic trials in the past 4 weeks.

研究实施时间:

Study execute time:

From 2023-02-01 00:00:00 To 2026-02-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-01 00:00:00 To 2026-02-01 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

50

Group:

Treatment group

Sample size:

干预措施:

太极

干预措施代码:

Intervention:

Tai Chi

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

注意力控制

干预措施代码:

Intervention:

Attention Control

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市中医医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai Municipal Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

西安大略和麦克马斯特大关节炎学指数

指标类型:

主要指标

Outcome:

Western Ontario and McMaster Universities Osteoarthritis Index

Type:

Primary indicator

测量时间点:

基线,第6周,第12周,第18周

测量方法:

Measure time point of outcome:

baseline, week 6, week 12, week 18

Measure method:

指标中文名:

等速肌力测试

指标类型:

次要指标

Outcome:

Isokinetic dynamometry

Type:

Secondary indicator

测量时间点:

基线,第12周

测量方法:

Measure time point of outcome:

baseline, week 12

Measure method:

指标中文名:

步态分析及表面肌电测试

指标类型:

次要指标

Outcome:

Gait and Surface electromyography test

Type:

Secondary indicator

测量时间点:

基线,第12周

测量方法:

Measure time point of outcome:

baseline, week 12

Measure method:

指标中文名:

生活质量简表

指标类型:

次要指标

Outcome:

Short Form for Quality of Life, SF-36

Type:

Secondary indicator

测量时间点:

基线,第6周,第12周,第18周

测量方法:

Measure time point of outcome:

baseline, week 6, week 12, week 18

Measure method:

指标中文名:

非甾体抗炎药物(NSAIDs)类型及服用剂量

指标类型:

次要指标

Outcome:

Dosage of NSAIDs

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 40 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由一名独立的统计学家使用SPSS(V 26.0)进行区组随机。符合条件的参与者将以1∶1的比例被随机分配到试组或对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

An independent statistician will use SPSS (version 26.0) to generate the random sequence with a randomized block size.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

因本试验干预手段的局限性,故不设盲。为保证屏蔽的实施,在试验实施前各研究人员将多次接受有关本研究规范实施的培训,均严格遵守各部门分离原则。

Blinding:

Due to nature of interventions, instructors and participants will not be blinded to the group allocations. The study coordinator will be responsible for informing participants of randomized results and arranging the schedule of interventions. The data managers, statisticians, evaluators will all be blinded to the group allocation throughout the entire procedure to minimize the risk of bias.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内公开,向研究者联系索取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact the researcher for the original data within 6 months after the trial is completed.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-03-14 10:45:33